SAN FRANCISCO--(BUSINESS WIRE)--Biotechnology is set for significant transformation in 2025 with an incoming political administration, rapid scientific advancements, and the convergence of technology and biology. Understand how significant changes in regulation, R&D, and partnering trends will shape the future of your life science company. Forge the investment and partnering relationships you need and get to know more than 75 industry media at Biotech Showcase 2025, taking place during J.P. Morgan Healthcare Week. Registration and partnering are now open!
Hosted by Demy-Colton and EBD Group, Biotech Showcase will return to the Hilton San Francisco Union Square January 13-15, 2025. A virtual event extends access to networking and insights January 21-22, 2025.
Attend corporate presentations and explore partnering and investment opportunities among 3,200+ attending investors, pharma companies, media, and private and small-cap public biotech and TechBio companies. Join curated discussions with leaders from companies like Novo Nordisk, Astellas Pharma, Morgan Stanley, AdvaMed, Stifel, BIO, Regeneron, Oppenheimer & Co., MRL Ventures Fund, Merck, among many others.
Anna Chrisman, Global Managing Director, EBD Group, said, “Biotech Showcase is the premier investor conference committed to creating a platform for private and micro-mid-cap biotechnology companies. It offers opportunities to explore the latest developments in biopharma and TechBio, with a robust lineup of presenting companies and thought leaders. We’re especially excited about the launch of the TechBio Showcase this year, featuring innovators applying tech-first approaches to biopharma innovation, marking a transformative shift in the industry.”
Opening day highlights:
The "New” Policy Landscape: Now That the Election is Behind Us, Where Do We Go from Here?
- Tim Opler, Managing Director, Global Healthcare Group, Stifel (Moderator)
- Grace Colón, CEO & Co-Founder, Inaya Therapeutics, BIO Executive Committee Member
- Nouhad Husseini, SVP, Business Development & Corporate Strategy, Regeneron Pharmaceuticals
- Tony Lanzone, Global Head, Consulting, Syneos Health
- Ted Love, Chair, Board of Directors, Biotechnology Innovation Organization (BIO)
- Beth Neitzel, Partner, Foley Hoag
- Scott Whitaker, President & CEO, AdvaMed
What is TechBio and What Impact Will It Have on Therapeutic Development?
- Daniella Kranjac, Founding General Partner, Avant Bio (Moderator)
- Alla Zamarayeva, Co-Founder & CEO, CellFE
- Ajit Singh, Managing Director and General Partner, Artiman Ventures
- David "DSO" Suendermann-Oeft, Founder & CEO, Modality.AI., Inc.
- Jeff Luber, President & CEO, Clairity
Closing day highlights:
Media Round-Up: Heard Around the Hilton
- Virginia Amann, CEO & Founder, ENTENTE Network (Moderator)
- Alex Philippidis, Senior Business Editor, GEN
- Adam Bluestein, Contributing Writer, Fast Company
- Allison DeAngelis, Reporter, Biotech Startups & Venture Capital, STAT News
- Ron Leuty, Senior Reporter, San Francisco Business Times
- Kyle LaHucik, Senior Reporter, Endpoints News
Sara Jane Demy, Founder & CEO of Demy-Colton, said, “We’ve curated a program featuring the voices shaping healthcare's future. We’re proud Biotech Showcase has become the leading kickoff event of the year, fostering meaningful connections among innovators, investors, and leaders to drive impactful innovation in 2025.”
For information about registering for Biotech Showcase or to apply to present or sponsor, please visit www.informaconnect.com/biotech-showcase/.
About Demy-Colton
Demy-Colton is a premier life sciences events organization committed to connecting industry leaders and fostering partnerships that advance life sciences innovation globally. Demy-Colton’s portfolio includes Biotech Showcase™, BioFuture™, and the Biotech CEO Summits in Europe and California, as well as virtual events designed to keep life sciences professionals connected year-round.
About EBD Group
EBD Group’s overriding mission is to help collaborations get started across the life sciences value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life sciences markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today, our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, ChinaBio® Partnering Forum, Rare Disease Innovation and Partnering Summit, and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. For more information, please visit www.ebdgroup.com.
